Hostname: page-component-76fb5796d-2lccl Total loading time: 0 Render date: 2024-04-25T11:34:45.731Z Has data issue: false hasContentIssue false
  • English
  • Français

A review of methylnaltrexone, a peripheral opioid receptor antagonist, and its role in opioid-induced constipation

Published online by Cambridge University Press:  22 May 2007

LAUREN SHAIOVA ,
FAYE RIM ,
DEBORAH FRIEDMAN  and
MARYAM JAHDI
LAUREN SHAIOVA
Affiliation:
Department of Neurology, Pain and Palliative Care, Memorial Sloan-Kettering Cancer Center, New York, New York
FAYE RIM
Affiliation:
Department of Neurology, Pain and Palliative Care, Memorial Sloan-Kettering Cancer Center, New York, New York
DEBORAH FRIEDMAN
Affiliation:
Sackler School of Medicine, Tel Aviv, Israel
MARYAM JAHDI
Affiliation:
Department of Neurology, Pain and Palliative Care, Memorial Sloan-Kettering Cancer Center, New York, New York
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: Opioid medications are frequently used in pain and palliative care patients with malignancy to manage symptoms such as pain and dyspnea. However, opiates are associated with various side effects. Constipation is a particularly problematic and common side effect of opioid pharmacology. Opioid antagonists have been studied in the management of opioid-induced constipation. Methylnaltrexone (MNTX) is a peripheral opioid antagonist currently under clinical investigation. It offers the potential to reverse undesirable side effects without reversing analgesia.

Methods: This article attempts to review existing clinical data, focusing on antagonism of opioid-induced adverse effects on the gastrointestinal system.

Results: MNTX seems to be well tolerated with limited or transient side effects. MNTX has been shown to improve oral-cecal transit times in opioid treated patients, induce laxation in chronic opioid users, and neither reverses the analgesic effects of morphine nor cause withdrawal symptoms.

Significance of results: Larger clinical trials of MNTX are still necessary to support its use as a standard for treatment of opioid-induced constipation.

Keywords

MethylnaltrexoneOpioid antagonistsOpioid-induced constipationCancerOncologyPain
Type
REVIEW ARTICLE
Information
Palliative & Supportive Care , Volume 5 , Issue 2 , June 2007 , pp. 161 - 166
Copyright
© 2007 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

Boyd, T.A. & Israel, R.J. (2004). Treatment of opioid-induced constipation in hospice patients with methylnaltrexone. Journal of Clinical Oncology, 22, 8279.Google Scholar
Brown, D.R. & Goldberg, L.I. (1985). The use of quaternary narcotic antagonists in opiate research. Neuropharmacology, 24, 181–191.Google Scholar
Cheskin, L., Chamia, T.N., Rolley, E.J., et al. (1995). Assessment of nalmefene glucuronide as a selective gut opioid antagonist. Drug and Alcohol Dependence, 39, 151–154.Google Scholar
Choi, Y.S. & Billings, J.A. (2002). Opioid antagonists: A review of their role in palliative care, focusing on use in opioid-related constipation. Journal of Pain and Symptom Management, 24, 71–90.Google Scholar
Cohen, S., Long, W.B., & Snape, W.J. (1979). Gastrointestinal motility. In Review of Physiology, Crane, R.K. (ed.), pp. 128–149. Baltimore: University Park Press.
Foss, J.F. (2001). A review of the potential role of methylnaltrexone in opioid bowel dysfunction. American Journal of Surgery, 182, 19S–26S.Google Scholar
Foss, J.F., Bass, A.S., & Goldberg, L.I. (1993). Dose related antagonism of the meetic effect of morphine by methylnaltrexone in dogs. Journal of Clinical Pharmacology, 33, 747–751.Google Scholar
Foss, J.F., O'Conner, M.F., Yuan, C.S., et al. (1997). Safety and tolerance of methylnaltrexone in healthy humans: A randomized placebo-controlled, intravenous, ascending dose pharmacokinetic study. Journal of Clinical Pharmacology, 37, 25–30.Google Scholar
Foss, J.F., Orelind, E., & Goldberg, L.I. (1996). The effects of methylnaltrexone on morphine-induced cough suppression in guinea pigs. Life Sciences, 59, 235–238.Google Scholar
Foss, J.F., Yuan, C.S., Roizen, M.F., et al. (1998). Prevention of apomorphine- or cisplatin-induced emesis in the dog by combination of methylnaltrexone and morphine. Cancer Chemotherapeutic Pharmacology, 42, 287–291.Google Scholar
Greenwood-Van Meerveld, B., Gardner, C.J., Little, P.J., et al. (2004). Preclinical studies of opioids and opioid antagonists on gastrointestinal function. Neurogastroenterology Motility, 16, 46S–53S.Google Scholar
Grond, S., Zech, D., & Diefenbach, C. (1994). Prevalence and pattern of symptoms in patients with cancer pain: A prospective evaluation of 1635 cancer patients referred to a pain clinic. Journal of Pain and Symptom Management, 9, 372–382.Google Scholar
Kurz, A. & Sessler, D. (2003). Opioid-induced bowel dysfunction: Pathophysiology and potential new therapies. Drugs, 63, 649–671.Google Scholar
Liu, M. & Wittbrodt, E. (2002). Low dose oral naloxone reverses opioid induced constipation and analgesia. Journal of Pain and Symptom Management, 23, 48–53.Google Scholar
Ponti, F. (2002). Methylnaltrexone progenics. Current Opinion in Investigational Drugs, 3, 614–620.Google Scholar
Sykes, N.P. (1996). An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliative Medicine, 10, 135–144.Google Scholar
Taguchi, A., Sharma, N., Saleem, R.M., et al. (2001). Selective postoperative inhibition of gastrointestinal opioid receptors. New England Journal of Medicine, 345, 935–940.Google Scholar
Thomas, J., Lipman, A., Slatkin, G., et al. (2005). A phase III double-blind placebo-controlled trial of methylnaltrexone for opioid induced constipation in advanced medical illness. Journal of Clinical Oncology, 23, 8003.Google Scholar
Vanegas, G., Ripamonti, C., & Sbanotto, A. (1998). Side effects of morphine administration in cancer patients. Cancer Nursing, 21, 289–297.Google Scholar
Yuan, C.S. (2004). Clinical status of methylnaltrexone, a new agent to prevent and manage opioid induced side effects. Supportive Oncology, 2, 111–122.Google Scholar
Yuan, C.S. & Foss, J.F. (2000a). Methylnaltrexone: Investigation of clinical applications. Drug Development Research, 50, 133–141.Google Scholar
Yuan, C.S. & Foss, J.F. (2000b). Oral methylnaltrexone for opioid induced constipation, research letter. Journal of the American Medical Association, 284, 1383–1384.Google Scholar
Yuan, C.S., Foss, J.F., & Moss, J. (1995). Effects of methylnaltrexone on morphine-induced inhibition of contraction in isolated guinea-pig ileum and human intestine. European Journal of Pharmacology, 276, 107–111.Google Scholar
Yuan, C.S., Foss, J., O'Conner, M., et al. (1996). Methylnaltrexone prevents morphine-induced delay in oral–cecal transit time without affecting analgesia: A double blind randomized placebo controlled trial. Clinical Pharmacology and Therapeutics, 59, 469–475.Google Scholar
Yuan, C.S., Foss, J., O'Conner, M., et al. (1998). Effects of low dose morphine on gastric emptying in healthy volunteers. Journal of Clinical Pharmacology, 38, 1017–1020.Google Scholar
Yuan, C.S., Foss, J.F., O'Conner, M., et al. (1999). Effects of intravenous methylnaltrexone on opioid induced gut motility and transit time changes in subjects receiving chronic methadone therapy: A pilot study. Pain, 83, 631–635.Google Scholar
Yuan, C.S., Foss, J.F., O'Conner, M., et al. (2000a). Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral–cecal transit time. Clinical Pharmacology Therapuetics, 67, 398–404.Google Scholar
Yuan, C.S., Foss, J.F., O'Conner, M., et al. (2000b). Methylnaltrexone for reversal of constipation due to chronic methadone use: A randomized controlled trial. Journal of the American Medical Association, 283, 367–372.Google Scholar
Yuan, C.S., Wei, G., Foss, J.F., et al. (2002). Effects of subcutaneous methylnaltrexone on morphine induced peripherally mediated side effects: A double blind randomized placebo controlled trial. Journal of Pharmacology and Experimental Therapuetics, 300, 118–123.Google Scholar
Zimmerman, D.M., Gidda, J.S., Cantrell, B.E., et al. (1994). Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine opioid antagonist for the treatment of gastrointestinal motility disorders. Journal of Medical Chemistry, 37, 2262–2265.Google Scholar